Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study

Authors: Giuseppe Vittorio De Socio, Giacomo Pucci, Franco Baldelli, Giuseppe Schillaci

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

The aim of the study was to assess the applicability of an algorithm predicting 10-year cardiovascular disease (CVD) generated in the setting of the Framingham Heart Study to a real-life, contemporary Italian cohort of HIV-positive subjects.

Methods

The study was an observational longitudinal cohort study. The probability for 10-year CVD events according to the Framingham algorithm was assessed in 369 consecutive HIV-positive participants free from overt CVD enrolled in 2004, who were followed for a median of 10.0 years (interquartile range, 9.1-10.1). Cardiovascular events included myocardial infarction, hospitalized heart failure, revascularized angina, sudden cardiac death, stroke, peripheral arterial disease.

Results

Over 3097 person-years of observation, we observed a total of 34 CVD events, whereas Framingham algorithm predicted the occurrence of 34.3 CVD events. CVD event rate was 11.0/1000 person-years of follow-up. In a receiver operating characteristics curve analysis, Framingham risk equation showed an excellent predictive value for incident CVD events (c-statistics, 0.83; 95% confidence interval, 0.76-0.90). In a multivariable Cox analysis, age, smoking and diabetes were independent predictors of CVD events. All-cause death rate was 20.0/1000 person-years of follow-up (n = 62 deaths). Causes of death included liver diseases (18), malignancies (14), AIDS-related (11); cardiovascular (9) and others (10). In a Cox analysis, age, AIDS diagnosis and chronic hepatitis were independent predictors of death.

Conclusions

Observed CVD events in HIV-infected patients were well predicted by Framingham algorithm. Established major CVD risk factors are the strongest determinants of CVD morbidity in an Italian contemporary cohort of HIV-positive subjects. Interventions to modify traditional risk factors are urgently needed in HIV people.
Literature
1.
go back to reference Guaraldi G, Cossarizza A, Franceschi C, Roverato A, Vaccher E, Tambussi G, et al. Life expectancy in the immune recovery era:the evolving scenario of the HIV epidemic in northern Italy. J Acquir Immune Defic Syndr. 2014;65:175–81.CrossRefPubMed Guaraldi G, Cossarizza A, Franceschi C, Roverato A, Vaccher E, Tambussi G, et al. Life expectancy in the immune recovery era:the evolving scenario of the HIV epidemic in northern Italy. J Acquir Immune Defic Syndr. 2014;65:175–81.CrossRefPubMed
2.
go back to reference De Socio GV, Ricci E, Parruti G, Maggi P, Madeddu G, Quirino T, et al. Chronological and biological age in HIV infection. J Inf Secur. 2010;61:428–30. De Socio GV, Ricci E, Parruti G, Maggi P, Madeddu G, Quirino T, et al. Chronological and biological age in HIV infection. J Inf Secur. 2010;61:428–30.
3.
go back to reference Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al., National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.CrossRefPubMed Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al., National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.CrossRefPubMed
4.
go back to reference D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117:743–53. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117:743–53.
5.
go back to reference Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D’Arminio Monforte A, et al., D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:a:D study. HIV Med. 2006;7:218–30.CrossRefPubMed Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D’Arminio Monforte A, et al., D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:a:D study. HIV Med. 2006;7:218–30.CrossRefPubMed
6.
go back to reference Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al., D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the data-collection on adverse effects of anti-HIV drugs (D:a:D) study. Eur J Prev Cardiol. 2016;23:214–23.CrossRefPubMed Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al., D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the data-collection on adverse effects of anti-HIV drugs (D:a:D) study. Eur J Prev Cardiol. 2016;23:214–23.CrossRefPubMed
7.
go back to reference Herrera S, Guelar A, Sorlì L, Vila J, Molas E, Grau M, et al. The Framingham function overestimates the risk of ischemic heart disease in HIV infected patients from Barcelona. HIV Clinical Trials. 2016;17:131–9.CrossRefPubMed Herrera S, Guelar A, Sorlì L, Vila J, Molas E, Grau M, et al. The Framingham function overestimates the risk of ischemic heart disease in HIV infected patients from Barcelona. HIV Clinical Trials. 2016;17:131–9.CrossRefPubMed
8.
go back to reference De Socio GV, Martinelli L, Morosi S, Fiorio M, Roscini AR, Stagni G, et al. Is estimated cardiovascular risk higher in HIV-infected patients than in the general population? Scand J Infect Dis. 2007;39:805–12. De Socio GV, Martinelli L, Morosi S, Fiorio M, Roscini AR, Stagni G, et al. Is estimated cardiovascular risk higher in HIV-infected patients than in the general population? Scand J Infect Dis. 2007;39:805–12.
9.
go back to reference Gruppo di Ricerca del Progetto CUORE. The Italian heart project- longitudinal studies. Ital Heart J. 2004;5:94S–101S. Gruppo di Ricerca del Progetto CUORE. The Italian heart project- longitudinal studies. Ital Heart J. 2004;5:94S–101S.
10.
go back to reference Ferrario M, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, Panico S, et al., CUORE Project Research Group. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE cohort study prediction equation. Int J Epidemiol. 2005;34:413–21.CrossRefPubMed Ferrario M, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, Panico S, et al., CUORE Project Research Group. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE cohort study prediction equation. Int J Epidemiol. 2005;34:413–21.CrossRefPubMed
11.
go back to reference Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al., SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.CrossRefPubMed Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al., SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.CrossRefPubMed
12.
go back to reference Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.CrossRefPubMed Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.CrossRefPubMed
13.
go back to reference Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J. 2000;21:365e70.CrossRef Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J. 2000;21:365e70.CrossRef
14.
go back to reference Raggi P, De Francesco D, Manicardi M, Zona S, Bellasi A, Stentarelli C, et al. Prediction of hard cardiovascular events in HIV patients. J Antimicrob Chemother. 2016;71:3515–8.CrossRefPubMed Raggi P, De Francesco D, Manicardi M, Zona S, Bellasi A, Stentarelli C, et al. Prediction of hard cardiovascular events in HIV patients. J Antimicrob Chemother. 2016;71:3515–8.CrossRefPubMed
16.
go back to reference Thompson-Paul AM, Lichtenstein KA, Armon C, Palella FJ Jr, Skarbinski J, Chmiel JS, et al. Cardiovascular disease risk prediction in the HIV outpatient study. Clin Infect Dis. 2016;63:1508–16.CrossRefPubMed Thompson-Paul AM, Lichtenstein KA, Armon C, Palella FJ Jr, Skarbinski J, Chmiel JS, et al. Cardiovascular disease risk prediction in the HIV outpatient study. Clin Infect Dis. 2016;63:1508–16.CrossRefPubMed
17.
go back to reference Feinstein MJ, Nance RM, Drozd DR, Ning H, Delaney JA, Heckbert SR, et al. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the centers for AIDS research network of integrated clinical systems. JAMA Cardiol. 2017;2:155–62.CrossRefPubMed Feinstein MJ, Nance RM, Drozd DR, Ning H, Delaney JA, Heckbert SR, et al. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the centers for AIDS research network of integrated clinical systems. JAMA Cardiol. 2017;2:155–62.CrossRefPubMed
18.
go back to reference Halpern SD, French B, Small DS, Saulsgiver K, Harhay MO, Audrain-McGovern J, et al. Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med. 2015;372:2108–17.CrossRefPubMedPubMedCentral Halpern SD, French B, Small DS, Saulsgiver K, Harhay MO, Audrain-McGovern J, et al. Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med. 2015;372:2108–17.CrossRefPubMedPubMedCentral
19.
go back to reference Moadel AB, Bernstein SL, Mermelstein RJ, Arnsten JH, Dolce EH, Shuter J. Randomized controlled trial of a tailored group smoking cessation intervention for HIV-infected smokers. J Acquir Immune Defic Syndr. 2012;61:208–15.CrossRefPubMedPubMedCentral Moadel AB, Bernstein SL, Mermelstein RJ, Arnsten JH, Dolce EH, Shuter J. Randomized controlled trial of a tailored group smoking cessation intervention for HIV-infected smokers. J Acquir Immune Defic Syndr. 2012;61:208–15.CrossRefPubMedPubMedCentral
20.
go back to reference De Socio GV, Ricci E, Maggi P, Parruti G, Celesia M, Orofino A, et al., CISAI Study Group. Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and hypertension study. J Hypertens. 2017;35:409–16.CrossRefPubMed De Socio GV, Ricci E, Maggi P, Parruti G, Celesia M, Orofino A, et al., CISAI Study Group. Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and hypertension study. J Hypertens. 2017;35:409–16.CrossRefPubMed
21.
go back to reference De Socio GV, Ricci E, Parruti G, Calza L, Maggi P, Celesia BM, et al. Statins and aspirin use in HIV-infected people: gap between European AIDS clinical society guidelines and clinical practice: the results from HIV-HY study. Infection. 2016;44:589–97.CrossRefPubMed De Socio GV, Ricci E, Parruti G, Calza L, Maggi P, Celesia BM, et al. Statins and aspirin use in HIV-infected people: gap between European AIDS clinical society guidelines and clinical practice: the results from HIV-HY study. Infection. 2016;44:589–97.CrossRefPubMed
22.
go back to reference Maggi P, De Socio GV, Cicalini S, D'Abbraccio M, Dettorre G, Di Biagio A, et al. Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians. New Microbiol. 2017;40:139–42.PubMed Maggi P, De Socio GV, Cicalini S, D'Abbraccio M, Dettorre G, Di Biagio A, et al. Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians. New Microbiol. 2017;40:139–42.PubMed
Metadata
Title
Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study
Authors
Giuseppe Vittorio De Socio
Giacomo Pucci
Franco Baldelli
Giuseppe Schillaci
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2510-x

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue